References
- World Health Organization. Depression [fact sheet no. 369]. 2012; Available at: http://www.who.int/mediacentre/factsheets/fs369/en/ [Last accessed 11 September 2014]
- Papakostas GI, Petersen T, Mahal Y, et al. Quality of life assessments in major depressive disorder: a review of the literature. General Hospital Psychiatry 2004;26:13-17
- Conti DJ, Burton WN. The economic impact of depression in a workplace. J Occupational Med 1994;36:983-8
- Kessler RC, Petukhova M, Sampson NA, et al. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 2012;21:169-84
- Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:655-79
- European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of depression. 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143770.pdf [Last accessed 1 August 2014]
- Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012;73:953-9
- Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012;27:215-23
- Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002;22:40-5
- Targum SD, Wedel PC, Robinson J, et al. A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of major depressive disorder. J Psychiatr Res 2013;47:944-54
- Khin NA, Chen Y-F, Yang Y, et al. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry 2011;72:464
- Khan A, Khan SR, Walens G, et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 2003;28:552-7
- Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2012;15:589
- Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012;26:1408-16
- Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin 2013;29:217-26
- Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 2012;28:1717-24
- Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol 2013;16:313-21
- Mahableshwarkar AR, Jacobsen PL, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Available at: http://www.psychiatry.org/learn/library–archives [Last accessed 2 August 2013]
- European Medicines Agency. Note for guidance on choice of control group in clinical trials. 2001. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002925.pdf [Last accessed 2 August 2013]
- Jin H, Shih PA, Golshan S, et al. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. J Clin Psychiatry 2013;74:10-18
- Greenberg RP, Fisher S. Suspended judgment. Seeing through the double-masked design: a commentary. Control Clin Trials 1994;15:244-6
- Perlis RH, Ostacher M, Fava M, et al. Assuring that double-blind is blind. Am J Psychiatry 2010;167:250-2
- Gartlehner G, Gaynes BN, Hansen RA, Lohr KN. Ranking antidepressants. Lancet 2009;373:1761
- Khan A, Bhat A, Kolts R, et al. Why has the antidepressant–placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neurosci Ther 2010;16:217-26
- Llorca PM, Lançon C, Brignone M, et al. PMH6 evolution of antidepressant efficacy over time: illustration with escitalopram. Value Health 2012;15:A334
- Glenny A-M, Altman D, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134, iii-iv
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58
- Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007;10:661-73
- European Medicines Agency. CHMP Assessment Report for Valdoxan (Agomelatine). EMEA/655251/2008. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000915/WC500046226.pdf [Last accessed September 2013]
- Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006;16:93-100
- Loo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17:239-47
- Stahl SM, Fava M, Trivedi MH, et al. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010;71:616-26
- Novartis. Clinical Trial Results Database. CAGO 178A2302. 2008. Available at: http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2626 [Last accessed August 2013]
- Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2010;30:135-44
- Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008;23:243-53
- Food and Drug Administration. Review and Evaluation of Clinical Data – Desvenlafaxine. NDA 21-991. 2008. Available at: http://drl.ohsu.edu/cdm/landingpage/collection/fdadrug [Last accessed August 2013]
- Tourian KA, Padmanabhan SK, Groark J, et al. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 2009;31(Pt 1):1405-23
- Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008;24:1877-90
- Lieberman DZ, Montgomery SA, Tourian KA, et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol 2008;23:188-97
- Iwata N, Tourian KA, Hwang E, et al. Efficacy and safety of desvenlafaxine 25 and 50mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract 2013;19:5-14
- Pfizer. Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder (NCT00798707). Available at: http://clinicaltrials.gov/ct2/show/NCT00824291?term=NCT00824291&rank=1 [Last accessed September 2013]
- Pfizer. Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder (NCT00824291). Available at: http://clinicaltrials.gov/ct2/show/NCT00824291?term=NCT00824291&rank=1 [Last accessed September 2013]
- Liebowitz MR, Tourian KA, Hwang E, et al. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder. BMC Psychiatry 2013;13:94
- Pfizer. Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder (NCT00863798). Available at: http://clinicaltrials.gov/ct2/show/NCT00863798?term=NCT00863798&rank=1 [Last accessed September 2013]
- European Medicines Agency. Withdrawal Assessment Report for ELLEFORE. 2009. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500064246.pdf [Last accessed August 2013]
- Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007;68:1663-72
- DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007;68:677-88
- Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007;22:338-47
- Feiger AD, Tourian KA, Rosas GR, Padmanabhan SK. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectrums 2009;14:41-50
- Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-15
- Lilly. Clinical Study Summary: Study F1J-MC-HMBH (Study Group A). 2004. Available at: http://www.lillytrials.com/results/Cymbalta.pdf [Last accessed September 2013]
- Lilly. Clinical Study Summary: Study F1J-MC-HMBH (Study Group B). 2004. Available at: http://www.lillytrials.com/results/Cymbalta.pdf [Last accessed September 2013]
- Pigott TA, Prakash A, Arnold LM, et al. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin 2007;23:1303-18
- Lilly. Clinical Study Summary: Study F1J-US-HMCR (Study Group A). 2007. Available at: http://www.lillytrials.com/results/Cymbalta.pdf [Last accessed September 2013]
- Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-70
- Lilly. Clinical Study Summary: Study F1J-MC-HMAY (Study Group A). 2005. Available at: http://www.lillytrials.com/results/Cymbalta.pdf [Last accessed September 2013]
- Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-99
- Lilly. Clinical Study Summary: Study F1J-MC-HMAT (Study Group B). 2004. Available at: http://www.lillytrials.com/results/Cymbalta.pdf [Last accessed September 2013]
- Lilly. Clinical Study Summary: Study F1J-MC-HMAT (Study Group A). 2004. Available at: http://www.lillytrials.com/results/Cymbalta.pdf [Last accessed September 2013]
- Lilly. Clinical Study Summary: Study F1J-MC-HMAQ (Study Group A). 2004. Available at: http://www.lillytrials.com/results/Cymbalta.pdf [Last accessed September 2013]
- Lilly. Clinical Study Summary: Study F1J-MC-HMAQ (Study Group B). 2004. Available at: http://www.lillytrials.com/results/Cymbalta.pdf [Last accessed September 2013]
- Lilly. Clinical Study Summary: Study F1J-MC-HMAY (Study Group B). 2006. Available at: http://www.lillytrials.com/results/Cymbalta.pdf [Last accessed September 2013]
- Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatric Psychiatry 2008;16:14-20
- Forest Laboratories Inc. Synopsis Clinical Study Report. SCT-MD-13. 2005. Available at: http://www.forestclinicaltrials.com/CTR/CTRController/CTRHome [Last accessed September 2013]
- Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-6
- Forest Laboratories Inc. Synopsis Clinical Study Report. SCT-MD-01. 2005. Available at: http://www.forestclinicaltrials.com/CTR/CTRController/CTRHome [Last accessed September 2013]
- Food and Drug Administration. Review and Evaluation of Clinical Data – Escitalopram. NDA 21-232. 2001. Available at: http://drl.ohsu.edu/cdm/landingpage/collection/fdadrug [Last accessed August 2013]
- Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-17
- Lundbeck A/S. Clinical Trial Report Summary – Study 99003. 2005. Available at: http://www.lundbeck.com/upload/trials/files/pdf/completed/99003_CTRS_final_30Dec2005.pdf [Last accessed August 2013]
- Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95-102
- Li Z, Huang M, Ichikawa J, et al. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 2005;30:1986-95
- Terranova JP, Chabot C, Barnouin MC, et al. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology (Berl) 2005;181:134-44
- Luttgen M, Elvander E, Madjid N, Ogren SO. Analysis of the role of 5-HT1A receptors in spatial and aversive learning in the rat. Neuropharmacology 2005;48:830-52
- Lydiard RB, Stahl SM, Hertzman M, Harrison WM. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry 1997;58:484-91
- Schneider LS, Nelson JC, Clary CM, et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003;160:1277-85
- Stahl SM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 2000;48:894-901
- Fabre LF, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995;38:592-602
- Food and Drug Administration. Review and Evaluation of Clinical Data – Sertraline. NDA 19-839. 1997. Available at: http://drl.ohsu.edu/cdm/landingpage/collection/fdadrug [Last accessed August 2013]
- Reimherr FW, Chouinard G, Cohn CK, et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990;51(Suppl B):18-27
- Rudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998;59:116-22
- Food and Drug Administration. Review and Evaluation of Clinical Data – Venlafaxine IR. NDA 20-151. 1993. Available at: http://drl.ohsu.edu/cdm/landingpage/collection/fdadrug [Last accessed August 2013]
- Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatric Psychiatry 2006;14:361-70
- Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-8
- Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106
- Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clinical Psychiatry 1997;9:157-64
- Food and Drug Administration. Review and Evaluation of Clinical Data – Venlafaxine XR. NDA 20-699. 1997. Available at: http://drl.ohsu.edu/cdm/landingpage/collection/fdadrug [Last accessed August 2013]
- Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999;56:171-81
- Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry 1997;58:393-8
- Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 2011;72:441-7
- Forest Laboratories Inc. Synopsis Clinical Study Report. SCSR_GNSC-04-DP-02_final. 2007. Available at: http://www.forestclinicaltrials.com/CTR/CTRController/CTRHome [Last accessed September 2013]
- Food and Drug Administration. Review and Evaluation of Clinical Data – Vilazodone. NDA 22-567. 2010. Available at: http://drl.ohsu.edu/cdm/landingpage/collection/fdadrug [Last accessed August 2013]
- Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:326-33
- Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012;22:482-91
- Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (LuAA21004) 15 and 20 mg/day: a randomised, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014;26:1408-16
- Mahableshwarkar AR, Jacobsen PL, Serenko M, et al. A duloxetine-referenced fixed dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult patients with MDD. 2013. Available at: http://www.psychiatry.org/learn/library–archives [Last accessed August 2013]
- Jacobsen PL, Mahableshwarkar AR, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10mg and 20mg in adults with major depressive disorder. 2013. Available at: http://www.psychiatry.org/learn/library–archives [Last accessed August 2013]
- Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
- Guy W. Clinical global impression scale. The ECDEU assessment manual for psychopharmacology–revised. Volume DHEW Publ No ADM 76 1976;338:218-22
- Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-care Evaluation. Chichester, UK: John Wiley & Sons, 2004
- European Medicines Agency. Guideline on Missing Data in Confirmatory Clinical Trials. 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/09/WC500096793.pdf [Last accessed 2 August 2013]
- Brown H, Prescott R. Applied Mixed Models in Medicine. Second Edition. Chichester, UK: Wiley, 2006
- Whitehead A. Meta-analysis of Controlled Clinical Trials. Statistics in Practice. Chichester, UK: Wiley, 2003
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
- Eckert L, Lancon C. Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. BMC Psychiatry 2006;6:30
- Harbord RM, Higgins JP. Meta-regression in Stata. Stata J 2008;8:493-519
- Higgins JP, Green S, Collaboration C. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org
- Schwan S, Hallberg P. Ranking antidepressants. Lancet 2009;373:1761
- Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 2011;155:772-85
- Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559-73
- Häggström LNR, Danchenko N, Poulsen L. A randomised, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment. Eur Neuropsychopharmacol 2013;23(Suppl 2):S412
- Williams V, Edin H, Hogue S, et al. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol 2010;24:489-96
- Taylor MJ, Rudkin L, Hawton K. Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials. J Affect Disord 2005;88:241-54
- Falissard B. Treatment of the mind, treatment of the brain: the same evidence-based medicine for both? Paris: 20th World Congress of the IACAPAP, 2012
- Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472